Aspirin resistance predicts adverse cardiovascular events: In patients with symptomatic peripheral artery disease

Texas Heart Institute Journal

Volumn 43, Issue 6, 2016, Pages 482-487

  Pasala, Tilak ^a,b   Hoo, Jennifer Soo ^a,b   Lockhart, Mary Kate ^a   Waheed, Rehan ^a,b   Sengodan, Prasanna ^a,b   Alexander, Jeffrey ^a,b   Gandhi, Sanjay ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Aspirin therapeutic use; Blood platelets drug effects; Lower extremity blood supply; Peripheral vascular diseases; Platelet aggregation inhibitors therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG RESISTANCE; DUAL ANTIPLATELET THERAPY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THORAX PAIN; AGED; BLOOD CLOTTING PARAMETERS; CHI SQUARE DISTRIBUTION; COMPLICATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; OHIO; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TERTIARY CARE CENTER; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

AGED; ASPIRIN; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OHIO; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85006851438     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: 10.14503/THIJ-14-4986     Document Type: Article

References (25)

1. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration [published erratum appears in BMJ 1994;308(6943): 1540]. BMJ 1994; 308(6921): 81-106.
2. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published erratum appears in BMJ 2002;324(7330): 141]. BMJ 2002;324(7329): 71-86.
3. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105(14): 1650-5.
4. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367(9510): 606-17.
5. Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol 2012;35(11): 673-81.
6. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007;120(7): 631-5.
7. Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral artery disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008; 52(21): 1736-42.
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038): 1329-39.
9. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78(3): 1003-7.
10. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103(6): 1245-53.
11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata- driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2): 377-81.
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease [published erratum appears in J Am Coll Cardiol 2006;48(9): 1918]. J Am Coll Cardiol 2003;41(6): 961-5.
13. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71(5): 397-403.
14. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108(1): 37-42.
15. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, Narin A. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207(1): 59-64.
16. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43(6): 1122-6.
17. Kilickesmez KO, Kocas C, Abaci O, Okcun B, Gorcin B, Gurmen T. Follow-up of aspirin-resistant patients with endstage kidney disease. Int Urol Nephrol 2013;45(4): 1097-102.
18. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336(7637): 195-8.
19. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: The PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 2013; 61(24): 2428-34.
20. Armstrong EJ, Anderson DR, Yeo KK, Singh GD, Bang H, Amsterdam EA, et al. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral artery disease. J Vasc Surg 2015;62(1): 157-165.e1.
21. Lotrionte M, Biondi-Zoccai GG. The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease. Curr Opin Cardiol 2008;23(5): 487-93.
22. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303(9): 841-8.
23. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58(19): 2020-45.
24. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6): 1309-11.
25. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004;43(6): 979-84.